Blueprint Medicines Profile

69.61
USD 1.98  2.77%
11%
17%

Exercise or conversion by Marion Dorsch of 2300 shares of Blueprint Medicines subject to Rule 16b-3

Blueprint Medicines Corporation insider trading alert for exercise of stock option (right to buy) by Marion Dorsch, Chief Scientific Officer, on September 19, 2018. This event was filed by Blueprint Medicines Corp with SEC on 2018-09-19. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Blueprint Medicines Summary

Blueprint Medicines Corporation (BPMC) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 181 people. Blueprint Medicines is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 3.36 B. Blueprint Medicines Corporation conducts business under Healthcare sector and is part of Biotechnology industry. This company has 43.89 M outstanding shares of which 3.22 M shares are currently shorted by private and institutional investors with about 8.0 trading days to cover. N/A currently holds about 613.46 M in cash with (113.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.98.
Check Blueprint Medicines Probability Of Bankruptcy

Ownership Allocation (%)

Blueprint Medicines Target Price Odds Analysis

Odds Below 69.61HorizonTargetOdds Above 69.61
7.45%30 days 69.61 92.43%
Based on normal probability distribution, the odds of Blueprint Medicines to move above current price in 30 days from now is about 92.43% (This Blueprint Medicines Corporation probability density function shows the probability of Blueprint Medicines Stock to fall within a particular range of prices over 30 days) .

Blueprint Medicines Top Holders

Blueprint Medicines Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares6.6 M417.4 M
Vanguard Group IncCommon Shares3.6 M230 M
View Blueprint Medicines Diagnostics

Blueprint Medicines Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Blueprint Medicines Key Fundamentals

Blueprint Medicines Against Markets

Blueprint Medicines Current Ratings

Blueprint Medicines Corporation 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
52 
Equity ratings for Blueprint Medicines Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 181 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Blueprint Medicines SEC Filings
Blueprint Medicines SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameBlueprint Medicines Corporation
President CEO, DirectorJeffrey AlbersView All
Thematic Classification
Currently Active Investing Idea
Cancer Fighters
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS U.S.A
Business Address38 Sidney Street
ExchangeBATS Exchange
CIK Number0001597264
CUSIP09627Y109
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.blueprintmedicines.com
Phone617 374 7580
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

Blueprint Medicines Directors

Blueprint Medicines Corporate Directors

Nicholas Lydon Director
Charles Rowland Independent Director
Michael Landsittel Interim Principal Accounting and Financial Officer and Sr. Director of Fin.
Check also Trending Equities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
Search macroaxis.com